Expanding Market Reach Gryphus Diagnostics has sold over 7 million BVBLUE tests worldwide and is actively seeking to expand both domestically and internationally, presenting a significant opportunity for distributors to add a proven rapidly growing diagnostic product to their portfolio.

Innovative Product Focus With its unique CLIA waived rapid sialidase test for bacterial vaginosis, Gryphus offers a specialized, easy-to-use diagnostic solution that appeals to healthcare providers seeking efficient point-of-care testing options.

Niche Diagnostic Specialty Operating within a specialized segment of medical equipment manufacturing, Gryphus provides opportunities for partners targeting clinics and medical facilities looking to enhance their bacterial vaginosis diagnostic capabilities.

Moderate Revenue Potential With annual revenues between 1 and 10 million dollars, Gryphus presents an accessible entry point for distributors aiming to expand their portfolio with a high-demand, branded diagnostic product in the reproductive health space.

Technology and Digital Presence Utilizing a robust online presence through its website and digital tools, Gryphus offers opportunities for partners to leverage marketing and e-commerce channels to promote and distribute BVBLUE effectively.